Liposomal Drug Formulations in the Treatment of Rheumatoid Arthritis
- 17 June 2011
- journal article
- review article
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 8 (4) , 1002-1015
Abstract
Liposomes have been extensively investigated as drug delivery systems in the treatment of rheumatoid arthritis (RA). Low bioavailability, high clearance rates and limited selectivity of several important drugs used for RA treatment require high and frequent dosing to achieve sufficient therapeutic efficacy. However, high doses also increase the risk for systemic side effects. The use of liposomes as drug carriers may increase the therapeutic index of these antirheumatic drugs. Liposomal physicochemical properties can be changed to optimize penetration through biological barriers and retention at the site of administration, and to prevent premature degradation and toxicity to nontarget tissues. Optimal liposomal properties depend on the administration route: large-sized liposomes show good retention upon local injection, small-sized liposomes are better suited to achieve passive targeting. PEGylation reduces the uptake of the liposomes by liver and spleen, and increases the circulation time, resulting in increased localization at the inflamed site due to the enhanced permeability and retention (EPR) effect. Additionally liposomal surfaces can be modified to achieve selective delivery of the encapsulated drug to specific target cells in RA. This review gives an overview of liposomal drug formulations studied in a preclinical setting as well as in clinical practice. It covers the use of liposomes for existing antirheumatic drugs as well as for new possible treatment strategies for RA. Both local administration of liposomal depot formulations and intravenous administration of passively and actively targeted liposomes are reviewed.Keywords
This publication has 97 references indexed in Scilit:
- Liposomal targeting of glucocorticoids to the inflamed synovium inhibits cartilage matrix destruction during murine antigen-induced arthritisInternational Journal of Pharmaceutics, 2011
- Optimizing the therapeutic index of liposomal glucocorticoids in experimental arthritisInternational Journal of Pharmaceutics, 2011
- Liposomal encapsulation enhances and prolongs the anti-inflammatory effects of water-soluble dexamethasone phosphate in experimental adjuvant arthritisArthritis Research & Therapy, 2010
- EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugsAnnals of the Rheumatic Diseases, 2010
- Separating therapeutic efficacy from glucocorticoid side-effects in rodent arthritis using novel, liposomal delivery of dexamethasone phosphate: long-term suppression of arthritis facilitates interval treatmentArthritis Research & Therapy, 2009
- Accumulation of liposome with Sialyl Lewis X to inflammation and tumor region: Application to in vivo bio-imagingBiochemical and Biophysical Research Communications, 2007
- Suppression of adrenal function in children with acute lymphoblastic leukemia following induction therapy with corticosteroid and other cytotoxic agentsThe Journal of Pediatrics, 2004
- Long‐term amelioration of rat adjuvant arthritis following systemic elimination of macrophages by clodronate‐containing liposomesArthritis & Rheumatism, 1995
- Sterically stabilized liposomesBiochimica et Biophysica Acta (BBA) - Reviews on Biomembranes, 1992
- Liposomes as drug carriersLife Sciences, 1977